DealForma

2023年2月10日

还记得2020年生物技术风险数字好吗?现在有这种想法。深入的数字生命科学风险投资者去年,DealForma克里斯Dokomajilar跟踪一个戏剧性的低迷的2022年,为一个新的正常,使医疗水平在2019年和2020年注册。但生物制药挑出了一些野蛮装卸一旦你把它们包。在他的年度看生物技术的前100名投资者,Dokomajilar发现接近200亿美元的510亿美元的生命科学投资跟踪去年针对平台和疗法。付费订阅要求贝丝斯奈德Bulik资深编辑更年期即将有一个重要的时刻——在超级碗。阿斯特拉正在潮热和盗汗周日的广播宣传运动。30秒的阿斯特拉商业运行在游戏中心技术术语,血管舒缩性症状或vm,对于更年期常见的信号。广告,女演员卡梅拉·莱利是一个记者在街上女人停下来问他们“一个急待解决的问题,”这是:“什么是虚拟机?“继续阅读端点免费订阅立即解锁这个故事,加入159200 +生物制药专业人士阅读每日端点,它是免费的。 SIGN UP Amber Tong Senior Editor For the second time in a year, Eliem Therapeutics is pivoting to a different neuro drug — but this time it’s being accompanied by drastic personnel changes. CEO Bob Azelby is leaving the biotech alongside COO and CFO Erin Lavelle and general counsel Jim Bucher. They are among 55% of the staffers who are being let go as part of a reorganization around the lead program. Eliem had 19 full-time employees and 12 part-time employees as of the end of 2021, according to its most recent disclosure. Shares $ELYM fell about 10% to $3 in pre-market trading. Read More Kyle LaHucik Associate Editor Oramed Pharmaceuticals will look at strategic alternatives after the biotech’s attempt at creating an insulin pill faltered in a Phase III last month. The New York biotech is still mining through the data from the Phase III of ORMD-0801, the failure of which tanked the stock by 70% in January. But to move forward, the board and executives are taking a fine look at the pipeline and “conducting a comprehensive review of strategic alternatives” that could include selling the business or its assets. Keep reading Endpoints with a free subscription Unlock this story instantly and join 159,200+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle LaHucik Associate Editor In an investor update Thursday morning, AbbVie left eight programs out of its pipeline highlights it shared with investors, as compared to what exists on the R&D page of its website, last refreshed in December. A Phase III study of Rinvoq in Takayasu arteritis , a rare group of disorders in which blood vessels become inflamed, was not included. The JAK inhibitor is approved for indications like rheumatoid arthritis and carries with it a black box warning. Keep reading Endpoints with a free subscription Unlock this story instantly and join 159,200+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Lei Lei Wu News Reporter The FDA’s cancer advisory committee gave its backing to a set of single-arm trials proposed by GSK to gain accelerated approval of its PD-1 inhibitor Jemperli in a rare subtype of locally advanced rectal cancer. The FDA’s Oncologic Drugs Advisory Committee voted 8-5 Thursday to support GSK’s proposal, which includes a single-arm trial of 100 patients with mismatch repair-deficient (MMR-deficient) or microsatellite instability-high (MSI-H) rectal cancer, along with an ongoing 30-patient trial. GSK said it’s planning to start the larger multi-site trial in the coming months. Keep reading Endpoints with a free subscription Unlock this story instantly and join 159,200+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle LaHucik Associate Editor Wall Street is welcoming a new drug developer to the stock markets for the second Friday in a row. Mineralys Therapeutics said Thursday night its initial public offering had priced at $16 per share, the high end of its proposed range, with an expected $192 million in proceeds. The biotech, nearing a Phase III for its lead asset, joins a small club of drug developers that has jumped onto the public markets recently after the IPO door appeared to slam shut last winter . Keep reading Endpoints with a free subscription Unlock this story instantly and join 159,200+ biopharma pros reading Endpoints daily — and it's free. SIGN UP